Your browser is no longer supported. Please, upgrade your browser.
Settings
FLXN Flexion Therapeutics, Inc. daily Stock Chart
FLXN [NASD]
Flexion Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.84 Insider Own0.40% Shs Outstand30.55M Perf Week37.04%
Market Cap823.93M Forward P/E- EPS next Y-2.44 Insider Trans-9.68% Shs Float30.38M Perf Month34.51%
Income-71.90M PEG- EPS next Q-0.72 Inst Own99.40% Short Float4.76% Perf Quarter30.10%
Sales- P/S- EPS this Y-31.90% Inst Trans16.98% Short Ratio3.26 Perf Half Y43.69%
Book/sh6.37 P/B4.23 EPS next Y29.50% ROA-41.80% Target Price36.14 Perf Year199.67%
Cash/sh6.73 P/C4.01 EPS next 5Y- ROE-50.60% 52W Range8.15 - 29.41 Perf YTD41.80%
Dividend- P/FCF- EPS past 5Y-29.60% ROI- 52W High-8.30% Beta-
Dividend %- Quick Ratio11.90 Sales past 5Y- Gross Margin- 52W Low230.92% ATR1.78
Employees95 Current Ratio11.90 Sales Q/Q- Oper. Margin- RSI (14)69.07 Volatility17.25% 7.54%
OptionableYes Debt/Eq0.16 EPS Q/Q-25.00% Profit Margin- Rel Volume1.47 Prev Close27.48
ShortableYes LT Debt/Eq0.11 EarningsMar 09 AMC Payout- Avg Volume443.47K Price26.97
Recom1.70 SMA2023.27% SMA5033.41% SMA20047.03% Volume649,943 Change-1.86%
Dec-22-16Initiated Raymond James Strong Buy
Sep-06-16Resumed Lake Street Buy $38
Jul-21-16Initiated Lake Street Buy $38
May-03-16Resumed Wells Fargo Outperform
Nov-04-15Initiated Cantor Fitzgerald Buy
Sep-09-15Reiterated Needham Buy $31 → $28
May-14-15Initiated Northland Capital Outperform $40
Mar-31-15Initiated MLV & Co Buy $38
Aug-14-14Initiated Summer Street Research Buy $25
Mar-10-14Initiated Needham Buy $26
Mar-28-17 09:00AM  Flexion Therapeutics to Present at Needham & Companys 16th Annual Healthcare Conference GlobeNewswire -6.08%
Mar-26-17 02:00PM  How I'd Play Biotech Buyout Rumors
Mar-24-17 04:19PM  Sanofi Could Acquire This Biotech, But Is $1 Billion Too Low?
09:30AM  Advances in Healthcare Technology and Osteoarthritis Drug Therapies Propel Two Healthcare Stocks Accesswire
Mar-23-17 05:36PM  Did Sanofi Just Bag This Biotech For $1 Billion? +33.38%
04:36PM  Here's Why Flexion Therapeutics Inc. Skyrocketed Today at Motley Fool
03:37PM  Flexion (FLXN) Stock Soars 35% on $1 Billion Sanofi Buyout
01:47PM  Flexion tops $800M in market cap on Sanofi buyout rumor at bizjournals.com
11:25AM  Sanofi Said to Be Near $1 Billion Deal for Flexion
Mar-16-17 01:04PM  FLEXION THERAPEUTICS INC Financials
Mar-10-17 08:43PM  Edited Transcript of FLXN earnings conference call or presentation 9-Mar-17 9:30pm GMT
05:01PM  FLEXION THERAPEUTICS INC Files SEC form 10-K, Annual Report
Mar-09-17 04:17PM  FLEXION THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Pr
04:01PM  Flexion Reports Year-End 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 Flexion Therapeutics Inc Earnings Release - After Market Close
Mar-03-17 09:00AM  Flexion Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Mar-02-17 10:42AM  Top Biotech Stocks With FDA Decisions in 2017 at Motley Fool
09:00AM  Flexion Therapeutics to Report Year-End 2016 Financial Results on March 9, 2017 GlobeNewswire
Feb-23-17 07:30AM  Flexion Therapeutics Initiates Clinical Trial to Evaluate the Safety of Repeat Administration of Zilretta (FX006) in Patients with Osteoarthritis of the Knee GlobeNewswire
Feb-15-17 09:00AM  Flexion Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference GlobeNewswire
Feb-07-17 07:30AM  Flexion Therapeutics Announces New Drug Application for Zilretta (FX006) Accepted by U.S. Food and Drug Administration GlobeNewswire
Dec-29-16 12:03PM  Todd Hagopian's Top Recommendations For 2017 at Forbes
Dec-22-16 07:04AM  Coverage initiated on Flexion Therapeutics by Raymond James
Dec-14-16 12:33AM  Should You Avoid Flexion Therapeutics Inc (FLXN)? at Insider Monkey
Dec-12-16 08:21AM  3 Drugs Heading to the FDA Soon at Motley Fool
07:20AM  Fast-growing Burlington biotech Flexion files for approval of lead drug at bizjournals.com
07:00AM  Flexion Therapeutics Submits New Drug Application for Zilretta to Treat Knee Osteoarthritis Pain GlobeNewswire
Dec-09-16 09:00AM  Flexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference GlobeNewswire
Dec-02-16 02:34PM  Should You Buy DHI Group Inc (DHX)? at Insider Monkey +5.80%
05:50AM  Hedge Funds Are Betting On Casella Waste Systems Inc. (CWST) at Insider Monkey
Nov-29-16 08:17AM  2 Red-Hot Biotechs to Buy Ahead of FDA Decisions at Motley Fool
Nov-28-16 02:21PM  Flexion Therapeutics, Inc. :FLXN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016
Nov-18-16 04:07PM  FLEXION THERAPEUTICS INC Files SEC form 8-K/A, Other Events, Financial Statements and Exhibits
Nov-17-16 03:34PM  Can Flexion Therapeutics Add Some Muscle to Your Portfolio? at Motley Fool
Nov-16-16 04:44PM  FLEXION THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -10.79%
12:55PM  Why Shares of Flexion Therapeutics, Inc., Lantheus Holdings Inc, and PDL BioPharma Inc Are Tanking Today at Motley Fool
09:00AM  Flexion Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire
Nov-15-16 04:01PM  Flexion Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Nov-14-16 06:20AM  FLEXION THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Nov-11-16 09:00AM  Flexion Therapeutics Announces Presentation of Phase 3 Data Demonstrating that Extended-Release Zilretta Achieves Clinically Significant Improvement of Pain, Stiffness and Function in Patients with Osteoarthritis of the Knee GlobeNewswire
Nov-08-16 05:34PM  Edited Transcript of FLXN earnings conference call or presentation 7-Nov-16 9:30pm GMT
Nov-07-16 04:48PM  FLEXION THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:47PM  Flexion Therapeutics reports 3Q loss
04:01PM  Flexion Therapeutics Reports Third Quarter 2016 Financial Results GlobeNewswire
07:07AM  Q3 2016 Flexion Therapeutics Inc Earnings Release - After Market Close
Nov-03-16 08:30AM  Flexion Therapeutics Announces that Analysis from Phase 3 Clinical Trial of Zilretta for Osteoarthritis of the Knee to be presented at AAHKS GlobeNewswire -8.63%
Nov-01-16 02:25PM  Trial suggests Flexions knee injection may be safer for diabetes patients at bizjournals.com
07:00AM  Flexion Therapeutics Reports Primary Endpoint Met in Clinical Trial Evaluating Investigational Drug Candidate Zilretta in Type 2 Diabetes Patients with Knee Osteoarthritis GlobeNewswire
Oct-28-16 08:30AM  Flexion Therapeutics to Report Third-Quarter 2016 Financial Results on November 7, 2016 GlobeNewswire
Oct-13-16 03:00PM  The Case For Flexion To Double By Mid-2017 at Forbes
Sep-29-16 08:30AM  Flexion Therapeutics Announces Appointment of John Magee as Vice President of Sales GlobeNewswire
Sep-21-16 11:01AM  3 Clinical-Stage Biotechs to Buy Ahead of FDA Decisions at Motley Fool
Sep-14-16 04:17PM  FLEXION THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers
08:30AM  Flexion Therapeutics Announces Appointment of Mark Stejbach to its Board of Directors GlobeNewswire
Sep-13-16 03:27PM  Flexion Therapeutics, Inc. :FLXN-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016
Sep-12-16 08:30AM  Flexion Therapeutics Announces Two Key Corporate Appointments GlobeNewswire
Aug-31-16 08:30AM  Flexion Therapeutics to Present at 2016 Wells Fargo Healthcare Conference GlobeNewswire
Aug-26-16 08:56AM  How Flexion (FLXN) Stock Stands Out in a Strong Industry
Aug-04-16 01:50PM  Seeing Some Good Action in Individual Stocks
Aug-03-16 09:30PM  Edited Transcript of FLXN earnings conference call or presentation 3-Aug-16 8:30pm GMT
05:15PM  Flexion Therapeutics reports 2Q loss
04:13PM  FLEXION THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:01PM  Flexion Therapeutics Reports Second-Quarter 2016 Financial Results GlobeNewswire
07:07AM  Q2 2016 Flexion Therapeutics Inc Earnings Release - After Market Close
Jul-29-16 06:31AM  Flexion Therapeutics (FLXN) Stock: Moving Average Crossover Alert
Jul-25-16 08:00AM  Flexion Therapeutics to Report Second-Quarter 2016 Financial Results on August 3, 2016 GlobeNewswire
Jul-12-16 08:15AM  Billionaires Are Piling Into These 3 Stocks at Motley Fool
Jul-06-16 11:10AM  Why Flexion Therapeutics Is Adding 3 New Executives to Its Ranks
08:00AM  Flexion Therapeutics Adds Three New Executives in Key Roles to Support the Planned Commercial Launch of Zilretta GlobeNewswire
Jun-24-16 03:03PM  Brexit Bargains: 3 Clinical-Stage Biotechs to Buy at Motley Fool -6.13%
Jun-16-16 04:31PM  FLEXION THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-08-16 04:48PM  FLEXION THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -12.37%
04:11PM  Flexion (FLXN) Stock Plunged Today After Announcing Stock Offering
03:02PM  Stocks inching toward record highs as oil jumps
01:56PM  Why Flexion Therapeutics Took a 12.8% Nosedive Today at Motley Fool
12:09PM  5 Stocks That Are Getting Battered and Bruised Today at Insider Monkey
10:46AM  Market Digging Metal and Mining Stocks
09:00AM  Flexion Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire
08:50AM  Flexion Therapeutics Raises More Capital in Secondary Offering at 24/7 Wall St.
Jun-07-16 06:21PM  3 Biotech Stocks Billionaires Are Buying That I'm Buying, Too at Motley Fool
04:07PM  FLEXION THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:05PM  Flexion Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Jun-05-16 03:01PM  Billionaires Are Buying Healthcare Stocks -- Should You Follow in Their Footsteps? at Motley Fool
Jun-04-16 08:00AM  Sleepy Bedford biotech Anika wakes up investors with recent success at bizjournals.com
Jun-02-16 01:00PM  Flexion Therapeutics, Inc. :FLXN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016
May-27-16 01:40PM  2 Sizzling-Hot Biotech Stocks to Buy at Motley Fool -9.87%
08:12AM  Flexion (FLXN) Zilretta Gets Positive FDA Guidance; Stock Up
May-26-16 08:32AM  FLEXION THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits +50.48%
07:00AM  Flexion Therapeutics Receives Positive Guidance from FDA on New Drug Application (NDA) Submission for Zilretta for Osteoarthritis of the Knee GlobeNewswire
May-20-16 06:00AM  Cynapsus Therapeutics Appoints Frederick Driscoll to Its Board of Directors GlobeNewswire +8.37%
May-13-16 12:42PM  Edited Transcript of FLXN earnings conference call or presentation 12-May-16 8:30pm GMT
May-12-16 04:19PM  FLEXION THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Notice of Delisting or Fa -8.81%
04:01PM  Flexion Therapeutics Reports First-Quarter 2016 Financial Results GlobeNewswire
10:44AM  FLEXION THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report
07:07AM  Q1 2016 Flexion Therapeutics Inc Earnings Release - Time Not Supplied
May-05-16 08:30AM  Flexion Therapeutics to Report First-Quarter 2016 Financial Results on May 12, 2016 GlobeNewswire
Apr-28-16 04:05PM  Flexion Therapeutics Enrolls First Patient in Phase 2 Trial of Zilretta Among Type 2 Diabetes Patients With Knee Osteoarthritis GlobeNewswire
Apr-07-16 08:00AM  Flexion Therapeutics to Present at 15th Annual Needham Healthcare Conference GlobeNewswire
Apr-04-16 09:00AM  Flexion Therapeutics Inc Conference Call to Discuss Clinical Trial Results for Zilretta at Osteoarthritis Research Society International 2016 World Congress scheduled for 9:00 am ET today +16.24%
07:16AM  FLEXION THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, a late-stage, intra-articular, extended-release investigational steroid treatment that has completed Phase 3 clinical trials for IA therapy for patients with moderate and severe osteoarthritis pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DRISCOLL FREDERICK WChief Financial OfficerMar 23Option Exercise7.893,00023,65810,777Mar 24 04:24 PM
DRISCOLL FREDERICK WChief Financial OfficerMar 23Sale23.003,00069,0007,777Mar 24 04:24 PM
Bodick NeilChief Medical OfficerMar 17Sale20.415,000102,03950,937Mar 20 07:42 PM
DRISCOLL FREDERICK WChief Financial OfficerFeb 28Option Exercise7.8930,000236,58341,211Mar 02 04:56 PM
DRISCOLL FREDERICK WChief Financial OfficerFeb 28Sale19.9733,434667,6797,777Mar 02 04:56 PM
Bodick NeilChief Medical OfficerFeb 24Sale19.155,00095,75855,937Feb 27 04:17 PM
Bodick NeilChief Medical OfficerJan 20Sale18.355,00091,74760,937Jan 23 07:10 PM
Bodick NeilChief Medical OfficerDec 21Sale18.4610,000184,62865,937Dec 22 04:40 PM
COLELLA SAMUEL DDirectorDec 01Buy16.3810,000163,80743,333Dec 05 02:40 PM
Clayman Michael D.President and CEONov 23Buy18.411,66730,68830,721Nov 23 08:17 PM
Clayman Michael D.President and CEONov 22Buy17.951,66629,90029,054Nov 23 08:35 AM
Clayman Michael D.President and CEONov 21Buy17.901,66629,82727,388Nov 22 02:28 PM
COLELLA SAMUEL DDirectorNov 21Buy18.0033,333599,99433,333Nov 22 06:40 PM
COLELLA SAMUEL DDirectorJun 21Buy13.6618,726255,76625,504Jun 22 01:36 PM
COLELLA SAMUEL DDirectorJun 20Buy13.846,77893,8336,778Jun 22 01:36 PM
MERRIFIELD C ANNDirectorJun 14Buy13.391,00013,3872,000Jun 16 05:59 PM
Versant Ventures III, LLC10% OwnerJun 08Buy14.00714,2859,999,9903,511,670Jun 10 09:16 PM
LUBASH BARBARA N10% OwnerJun 08Buy14.00714,2859,999,9903,511,670Jun 10 09:40 PM
COLELLA SAMUEL DDirectorJun 08Buy14.00714,2859,999,9903,511,670Jun 10 08:25 PM
Clayman Michael D.President and CEOMay 23Option Exercise0.1610,3691,68625,722May 24 05:26 PM
Clayman Michael D.President and CEOMay 20Buy10.412,00020,81013,568May 23 04:04 PM
Clayman Michael D.President and CEOMay 19Buy9.652,00019,29711,568May 20 05:52 PM
Bodick NeilChief Medical OfficerMay 19Buy10.008508,50075,937May 20 05:51 PM
Clayman Michael D.President and CEOMay 18Buy10.232,00020,4659,568May 19 05:30 PM
Bodick NeilChief Medical OfficerMay 18Buy10.202,10021,42075,087May 19 05:29 PM
DRISCOLL FREDERICK WChief Financial OfficerMay 17Buy9.872,50024,6688,434May 18 05:23 PM
Bodick NeilChief Medical OfficerMay 17Buy9.608007,68072,987May 18 05:21 PM
Clayman Michael D.President and CEOMay 17Buy9.732,00019,4657,568May 18 05:22 PM
DRISCOLL FREDERICK WChief Financial OfficerMay 16Buy9.192,50022,9725,934May 17 06:12 PM
Clayman Michael D.President and CEOMay 16Buy9.512,00019,0255,568May 17 06:10 PM
Bodick NeilChief Medical OfficerMay 16Buy9.221,25011,52572,187May 17 06:08 PM